Company announcement
19 April 2018
NeuroSearch A/S refers to the article in MedWatch on 19 April 2018 relating to Teva giving up the development of the investigational medicinal product, Pridopidine.
NeuroSearch A/S hereby informs that it is in discussions with regard to the potential sale of its rights to Pridopidine for a small seven figure amount in DKK.
NeuroSearch A/S is also still investigating the potential sale of the company, but there is no certainty that these investigations will result in such a sale.
NeuroSearch A/S will provide further information if and when required to do so.
Contact person:
Allan Andersen, CEO, +45 4016 3864
About NeuroSearch
NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S.
Attachment
